Ellagic Acid and Iron: what the published research says
PubMed indexes 8 records that name Ellagic Acid and Iron together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Ellagic Acid and Iron. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
A study appearing here is not proof that an interaction exists. Two substances can be named together in a paper that never tested them in combination, and a source listed as background may cover only one of them.
Findings are quoted from each abstract as the authors wrote them. NutriStack has not re-analysed, pooled, or reconciled them, and they may disagree with each other.
NutriStack’s own interaction assessment for this pair is not published here. It has not completed qualified-human clinical review, so it is withheld from search. See the publication gate.
Nothing here is medical advice. Decisions about prescription medication and supplements belong with your prescriber or pharmacist, who can see your full regimen.
The research
8 studies naming Ellagic Acid and Iron.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
“This work provides a rational design strategy for high-performance environmental catalytic materials by systematically investigating the molecular characteristics of the EA-based iron coordination complex with prominent electron delocalization properties caused by polyphenolic structure of EA, and the various PDS activation pathways resulting therefrom.”
“Mechanistic analysis further revealed that the PFE-PEG NPs suppressed melanoma glycolysis, thereby disrupting metabolic homeostasis in the tumor microenvironment. This work establishes a multimodal therapeutic strategy that coactivates ferroptosis and apoptosis while disrupting tumor metabolic dependencies, thereby achieving synergistic antitumor efficacy against melanoma.”
Food research international (Ottawa, Ont.) · 2025 · PMID 40467263
Animal study
“Importantly, exogenous TGFβ supplementation abolished the antiferroptotic effects of EA, further confirming TGFβ/Smad signaling as the central mechanistic pathway through which EA exerts its protective function. Collectively, our results establish EA as a novel regulator of the TGFβ/Smad axis, effectively mitigating iron overload-driven ferroptosis and subsequent hepatic injury and thereby offering a potential therapeutic strategy for iron-related hepatopathies.”
“EA revealed hepatoprotective activity against iron overload-induced toxicity through scavenging free radicals, inhibiting excess ROS production, normalizing liver damage parameters and upregulating caspase-3, PARP expression. Collectively, our findings support the possible use of the natural antioxidant EA as a promising candidate against iron-overloaded diseases.”
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2017 · PMID 27829207
“Furthermore, the EA antioxidant effectiveness was inversely proportional to the Fe(III) concentration, suggesting a competition with EDTA. In conclusion, the results indicate that EA may prevent in vitro free radical formation when it forms a complex with iron ions.”
Names both Ellagic Acid and Iron in its title.
Limitations
What this evidence cannot tell you.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
Selection. These records were found by searching PubMed titles and abstracts for both substance names alongside interaction and pharmacokinetic terms. Relevant work that phrases things differently, or is not indexed in PubMed, will be missing.
No effect size. The quoted conclusions are the authors’ words about their own study. We have not extracted effect direction or magnitude, and a single study’s conclusion is not a consensus.
Population mismatch. Findings in healthy volunteers, animals, or a specific patient group may not transfer to you, your dose, or your formulation.
Absence is not safety. Few published studies means the combination is under-studied, which is not the same as established as safe.
Nearby evidence
Other pairs with published research.
Pages covering Ellagic Acid or Iron alongside a different substance.
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Ellagic Acid, Iron, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
